* Iteos Therapeutics Inc ITOS.OQ reported a quarterly
adjusted
loss of $1.05 per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -90 cents. The mean expectation of six analysts for the
quarter was for a loss of 89 cents per share. Wall Street
expected results to range from $-1.42 to 52 cents per share.
* Reported revenue was zero; analysts expected $16.67
million.
* Iteos Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.05.
* The company reported a quarterly loss of $45.36 million.
* Iteos Therapeutics Inc shares had fallen by 8.1% this
quarter and lost 14.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Iteos
Therapeutics Inc is 33.50
This summary was machine generated from LSEG data November 12 at
07:25 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.89 -1.05 Missed
Jun. 30 2024 -1.04 -0.18 Beat
Mar. 31 2024 -1.26 -1.07 Beat
Dec. 31 2023 -1.03 -0.85 Beat